Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sign Of The Times: Late-Stage Cancer Vaccines On Display At ASCO

This article was originally published in The Pink Sheet Daily

Executive Summary

Vindicated by the approvals of Provenge and Yervoy, a host of therapeutic cancer vaccines is working through late-stage trials with the regulatory finish line in sight, and some of those companies will be presenting data at the American Society of Clinical Oncology meeting in Chicago June 1-5.


Related Content

Generex Likes Chances For Partnering AE37 Breast Cancer Vaccine
In Europe, A Public-Private Effort Could Shed Light On The Tricky Business Of Cancer Vaccines
New EU-Funded Consortium Aims To Develop Targeted Cancer Vaccines
Scancell’s DNA Plasmid-Cancer Vaccine Shows Promise In Melanoma
ScanCell’s DNA Plasmid-Cancer Vaccine Shows Promise In Melanoma
BMS’ Andreotti Talks BD Beyond 2015
Selected Active Cancer Vaccines In Development
Cancer Vaccines Headed For Mainstream
Therapeutic Cancer Vaccines Can Use Adjuvants, FDA Says
Bristol Basks In Broad Ipilimumab Label, Sets High Price


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts